ArticleDiscover oncology2025
Early antibiotic exposure does not affect prognosis in patients with advanced gastric cancer treated with PD-1 inhibitors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo explore the prognostic impact of antibiotic exposure during programmed death receptor-1 (PD-1) inhibitor therapy in patients with advanced gastric cancer (AGC).
methodsData of 218 AGC patients treated with PD-1 inhibitors were retrospectively collected. The impact of antibiotic exposure in different time windows and other clinical factors on the prognosis of AGC patients was analyzed.
resultsAntibiotic exposure prior to PD-1 inhibitor therapy (pATB) was significantly correlated with peritoneal metastasis (P = 0.007). Concurrent antibiotic exposure (cATB) was associated with different treatment types (P = 0.012) and ECOG PS (P < 0.001). In terms of prognosis, neither pATB nor cATB exposure significantly affected overall survival (OS) (P = 0.804, P = 0.324), whereas cATB exposure was a predictive factor for progression free survival (PFS) (P = 0.007). Treatment lines (P < 0.001) and cATB exposure (P = 0.027) were independent prognostic variables for predicting PFS according to multivariate Cox analysis. Furthermore, it was found that treatment lines (P = 0.004) and peritoneal metastasis (P = 0.002) were independent prognostic variables that predicted OS. However, in the sensitivity analysis, nine patients experienced varying degrees of delay in subsequent treatment after cATB exposure, leading to disease progression. Exclusion of these nine patients revealed that adjusted cATB exposure was not a prognostic factor for PFS in AGC patients (P = 0.074).
conclusionThere is no evidence that antibiotics affect the long-term OS prognosis of AGC patients receiving PD-1 inhibitor therapy. Therefore, physicians should not delay PD-1 inhibitor combination treatment regimens in AGC patients who have recently received antibiotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.